Kwality Pharmaceuticals Ltd
Incorporated in 1983, Kwality Pharma is in the business of manufacturing & trading in Pharmaceuticals & allied products[1]
- Market Cap ₹ 905 Cr.
- Current Price ₹ 872
- High / Low ₹ 961 / 356
- Stock P/E 26.3
- Book Value ₹ 234
- Dividend Yield 0.00 %
- ROCE 15.9 %
- ROE 13.7 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Company has delivered good profit growth of 31.2% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 34.2%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 100 to 138 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
62 | 60 | 52 | 76 | 95 | 137 | 165 | 138 | 261 | 456 | 251 | 307 | 340 | |
58 | 56 | 49 | 70 | 86 | 125 | 149 | 124 | 231 | 284 | 190 | 241 | 266 | |
Operating Profit | 3 | 4 | 4 | 6 | 9 | 12 | 15 | 14 | 29 | 172 | 61 | 67 | 75 |
OPM % | 5% | 6% | 7% | 8% | 9% | 8% | 9% | 10% | 11% | 38% | 24% | 22% | 22% |
0 | 0 | 1 | 0 | 2 | 1 | 1 | 4 | 2 | 4 | -14 | -5 | -5 | |
Interest | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 7 | 10 | 11 |
Depreciation | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 4 | 6 | 11 | 15 | 20 | 18 |
Profit before tax | 2 | 2 | 2 | 3 | 6 | 8 | 11 | 11 | 22 | 162 | 26 | 31 | 40 |
Tax % | 27% | 47% | 29% | 39% | 41% | 38% | 31% | 24% | 29% | 26% | 24% | 24% | |
1 | 1 | 1 | 2 | 3 | 5 | 8 | 8 | 15 | 120 | 19 | 24 | 29 | |
EPS in Rs | 1.66 | 0.95 | 1.32 | 1.89 | 3.31 | 4.51 | 7.28 | 8.12 | 14.86 | 115.70 | 18.76 | 23.11 | 28.01 |
Dividend Payout % | 0% | 0% | 0% | 0% | 9% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 18% |
5 Years: | 13% |
3 Years: | 6% |
TTM: | 30% |
Compounded Profit Growth | |
---|---|
10 Years: | 41% |
5 Years: | 31% |
3 Years: | 24% |
TTM: | 23% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 99% |
3 Years: | 4% |
1 Year: | 124% |
Return on Equity | |
---|---|
10 Years: | 30% |
5 Years: | 33% |
3 Years: | 34% |
Last Year: | 14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4 | 4 | 4 | 5 | 5 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Reserves | 8 | 13 | 15 | 18 | 21 | 21 | 28 | 37 | 52 | 172 | 192 | 216 | 232 |
6 | 6 | 8 | 13 | 19 | 26 | 28 | 35 | 41 | 54 | 90 | 98 | 103 | |
11 | 12 | 10 | 17 | 27 | 41 | 40 | 53 | 65 | 106 | 71 | 74 | 52 | |
Total Liabilities | 29 | 35 | 38 | 52 | 72 | 98 | 107 | 135 | 169 | 343 | 364 | 398 | 397 |
10 | 11 | 11 | 11 | 16 | 19 | 28 | 42 | 56 | 91 | 120 | 138 | 137 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 12 | 14 | 0 | 0 |
Investments | 1 | 3 | 4 | 5 | 7 | 9 | 8 | 8 | 9 | 4 | 4 | 4 | 4 |
18 | 21 | 23 | 36 | 50 | 70 | 71 | 86 | 102 | 236 | 226 | 256 | 256 | |
Total Assets | 29 | 35 | 38 | 52 | 72 | 98 | 107 | 135 | 169 | 343 | 364 | 398 | 397 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
8 | -0 | 1 | -3 | 4 | -0 | 12 | 6 | 26 | 59 | 42 | 43 | |
-1 | -4 | -1 | -2 | -7 | -6 | -11 | -17 | -23 | -63 | -48 | -26 | |
-5 | 3 | 1 | 5 | 5 | 5 | -2 | 12 | 1 | 6 | 1 | -17 | |
Net Cash Flow | 2 | -2 | 0 | 0 | 1 | -1 | -1 | 1 | 4 | 2 | -5 | -0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 42 | 41 | 63 | 95 | 87 | 99 | 86 | 80 | 53 | 57 | 107 | 138 |
Inventory Days | 33 | 58 | 61 | 54 | 72 | 54 | 34 | 94 | 38 | 97 | 310 | 187 |
Days Payable | 31 | 58 | 40 | 61 | 67 | 79 | 52 | 96 | 58 | 63 | 117 | 106 |
Cash Conversion Cycle | 44 | 41 | 85 | 89 | 92 | 74 | 68 | 78 | 33 | 91 | 300 | 219 |
Working Capital Days | 35 | 60 | 81 | 87 | 79 | 76 | 62 | 99 | 48 | 89 | 212 | 196 |
ROCE % | 14% | 12% | 11% | 15% | 19% | 19% | 21% | 18% | 26% | 97% | 18% | 16% |
Documents
Announcements
-
Kwality Pharma Received The Approval For Leuprorelin Acetate For Injectable Suspension As A Site Variation From Greece
6 Nov - Approval for Leuprorelin Acetate marks entry into Europe.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
6 Nov - NEWSPAPER PUBLICATION OF RESULTS FOR QUARTER AND HALF YEAR ENDED 30-09-2024.
-
Board Meeting Outcome for Submission Of Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2024
30 Oct - Approved unaudited financial results for Q2 FY25.
- Submission Of Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2024 30 Oct
-
Board Meeting Intimation for Consider And Approve The Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2024.
22 Oct - Board meeting scheduled to approve financial results.
Business Overview:[1][2]
KPL is in an ANVISA and EU GMP certified manufacturer of all pharma products including complex molecules across all dosage forms including niche Biologics. It has a portfolio of 3000+ formulations across 25+ therapeutic areas with categories including generics, cephalosporin, beta-lactam, oncology & biologics. It manufactures and deals in drugs intermediates, chemicals, extracts, alkaloids and other pharmaceutical goods, toilet requisites, medicines, beverages and other medical preparations